PKDL—A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India

PLoS Neglected Tropical Diseases

Volumn 9, Issue 10, 2015, Pages

  Ganguly, Swagata ^a,b   Saha, Pabitra ^a,c   Chatterjee, Moytrey ^a   Roy, Surajit ^a   Ghosh, Tamal Kanti ^d   Guha, Subhasish K ^a   Kundu, Pratip K ^a   Bera, Dilip K ^a   Basu, Nandita ^a   Maji, Ardhendu K ^a  

^a CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

^b NRS MEDICAL COLLEGE   (India)

^c Matigara   (India)

^d Medinipur Medical College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE; STIBOGLUCONATE SODIUM; ANTIMONY GLUCONATE; ANTIPROTOZOAL AGENT; PHOSPHORYLCHOLINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INDIA; MALE; MASS SCREENING; MYCOBACTERIUM LEPRAE; NONHUMAN; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; SENSITIVITY AND SPECIFICITY; SKIN DEFECT; SKIN LEISHMANIASIS; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; ANALOGS AND DERIVATIVES; ANIMAL; COMPLICATION; EPIDEMIOLOGICAL MONITORING; LEISHMANIASIS, CUTANEOUS; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PREVALENCE; RECURRENT DISEASE; RURAL POPULATION; TRANSMISSION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, INFECTIOUS; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; INDIA; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; POLYMERASE CHAIN REACTION; PREVALENCE; RECURRENCE; RURAL POPULATION; YOUNG ADULT;

EID: 84959195723     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004138     Document Type: Article

References (36)

1. Boelaert M, Meheus F, Sanchez A, Singh SP, Vanlerberghe V, Picado A, et al. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Trop Med Int Health. 2009; 14: 639–644. doi: 10.1111/j.1365-3156.2009.02279.x19392741
2. Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, Foschi A, et al. Post kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol. 2007; 157: 1032–1036. 17854365
3. Ganguly S, Das NK, Barbhuiya JN, Chatterjee M, Post kala-azar dermal leishmaniasis–an overview. Int J Dermatol. 2010; 49: 921–931. doi: 10.1111/j.1365-4632.2010.04558.x21128917
4. Ramesh V, Mukherjee A, Post kala-azar dermal leishmaniasis. Int J Dermatol. 1995; 34: 85–91. 7737782
5. Rahman KM, Islam S, Rahman MW, Kenah E, Galive CM, Zahid MM, et al. Increasing incidence of post kala-azar dermal leishmaniasis in a population-based study in Bangladesh. Clin Infect Dis. 2010; 50: 73–76. doi: 10.1086/64872719951168
6. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM, Post kala- azar dermal leishmaniasis. Lancet Infect Dis. 2003; 3: 87–98. 12560194
7. Das VN, Ranjan A, Pandey K, Singh D, Verma N, Das S, et al. Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India. Am J Trop Med Hyg. 2012; 86(6): 959–961. doi: 10.4269/ajtmh.2012.11-046722665600
8. World Health Organization. Regional Technical Advisory Group on Kala-azar Elimination. Report of the first meeting, Manesar, Haryana, 20–23 December 2004. Regional Office for South-East Asia, New Delhi, October. 2005.
9. Addy M, Nandy A, Ten years of kala-zar in West Bengal, Part I. Did post kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas?Bull World Health Organ. 1992; 70: 341–346. 1638662
10. Desjeux P, Ghosh RS, Dhalaria P, Strub-Wourgaft N, Zijlstra EE, Report of the Post Kala-Azar Dermal Leishmaniasis (PKDL) consortium meeting, New Delhi, India. Parasites & Vectors. 2013; 6: 196. doi: 10.1186/1756-3305-6-19623819611
11. Mondal D, Khan MG, Recent advances in post kala-azar dermal leishmaniasis. Curr Opin Infect Dis. 2011; 24: 418–422. doi: 10.1097/QCO.0b013e32834a8ba121885919
12. Uranw S, Post kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000–2010). PLoS Negl Trop Dis. 2011; 5: e1433. doi: 10.1371/journal.pntd.000143322206030
13. Das VNR, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, et al. Development of Post–Kala-Azar Dermal Leishmaniasis (PKDL) in Miltefosine-Treated Visceral Leishmaniasis. Am J Trop Med Hyg. 2009; 80(3): 336–338. 19270277
14. Thakur CP, Kumar A, Mitra G, Thakur S, Sinha PK, Das P, et al. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J Med Res. 2008; 128: 38–44. 18820357
15. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002; 347: 1739–1746. 12456849
16. Kumar D, Ramesh V, Verma S, Ramam M, Salotra P, Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Ann Trop Med Parasitol. 2009; 103: 727–730. doi: 10.1179/000349809X1255410696343820030997
17. Pandey K, Das VNR, Singh D, Das S, Lal CS, Verma N, et al. Post kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India. J Clin Microbiol. 2012; 50: 1478–1479. doi: 10.1128/JCM.05966-1122278840
18. Zijlstra EE, Alvar J, The Post Kala-Azar dermal Leishmaniasis (PKDL) atlas. The Lancet Infect Dis. 2013; 3(2): 87–98.
19. Mondal D, Nasrin KN, Huda MM, Kabir M, Hossain MS, Kroeger A, et al. Enhanced case detection and improved diagnosis of PKDL in a kala-azarendemic area of Bangladesh. PLoS Negl Trop Dis. 2010; 4: e832. doi: 10.1371/journal.pntd.000083220957193
20. Garg VK, Sudha A, Sudha R, Joshi A, Agarwalla A, Das ML, et al. Post-kala-azar dermalleishmaniasis in Nepal. Int J Dermatol. 2001; 40: 179–184. 11422520
21. Salotra P, Singh R, Challenges in the diagnosis of post kala-azar dermal leishmaniasis. Indian J Med Res. 2006; 123(3): 295–310. 16778312
22. Osman OF, Oskam L, Kroon NC, Schoone GJ, Khalil EAG, El-Hassan AM, et al. Use of PCR for diagnosis of post-kala-azar dermal leishmaniasis. J Clin Microbiol. 1998; 36: 1621–1624. 9620389
23. Salotra P, Sreenivas G, Gregory P, Development of a Species-Specific PCR Assay for Detection of Leishmania donovani in Clinical Samples from Patients with Kala-Azar and Post-Kala-Azar Dermal Leishmaniasis. J Clin Microbiol. 2001; 39(3): 849–854. 11230394
24. Sreenivas G, Ansari NA, Kataria J, Salotra P, Nested PCR Assay for Detection of Leishmania donovani in Slit Aspirates from Post-Kala-Azar Dermal Leishmaniasis Lesions. J Clin Microbiol. 2004; 42(4): 1777–1778. 15071047
25. Singh R, Kumar D, Ramesh V, Negi NS, Singh S, Salotra P, Visceral Leishmaniasis, or Kala Azar (KA): High Incidence of Refractoriness to Antimony Is Contributed by Anthroponotic Transmission via Post-KA Dermal Leishmaniasis. J Infect Dis. 2006; 194: 302–306. 16826477
26. Nasreen SA, Hossain MA, Paul SK, Mahmud MC, Ahmed S, Ghosh S, et al. PCR-based detection of Leishmania DNA in skin samples of post kalaazar dermal leishmaniasis patients from an endemic area of Bangladesh. Jpn J Infect Dis. 2012; 65(4): 315–317. 22814154
27. Singh RP, Picado A, Alam A, Hasker E, Singh SP, Ostyn B, et al. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India. Trop Med Int Health. 2012; 17: 1345–1348. doi: 10.1111/j.1365-3156.2012.03067.x22882665
28. Bern C, Jha SN, Joshi AB, Thakur GD, Bista MB, Use of recombinant k39 dipstick test and the direct agglutination test in a setting endemic for visceral leishmaniasis in Nepal. Am J Trop Med Hyg. 2000; 63: 153–157. 11388508
29. Salotra P, Sreenivas G, Ramesh V, Sundar S, A simple and sensitive test for field diagnosis of post kala-azar dermal leishmaniasis. British J Dermatol. 2001a; 145: 630–632.
30. Salotra P, Sreenivas G, Beena KR, Mukherjee A, Ramesh V, Parasite detection in patients with post kala-azar dermal leishmaniasis in India: a comparison between molecular and immunological methods. J Clinical Pathol. 2003; 56: 840–843.
31. Osman OF, Kager PA, Zijlstra EE, El-Hassan AM, Oskam L, Use of PCR on lymph-node samples as test of cure of visceral leishmaniasis treatment. Ann Trop Med Parasitol. 1997; 91: 845–850. 9625941
32. Sundar S, Singh A, Chakravarty J, Rai M, Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis. Scientific World J. 2015.
33. Ramesh V, Katara GK, Verma S, Salotra P, Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. Br J Dermatol. 2011; 165:411–414. doi: 10.1111/j.1365-2133.2011.10402.x21561437
34. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the centre of the Indian epidemic. Clin Infect Dis. 2000; 31:1104–1107. 11049798
35. Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BMS, et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg. 2003; 97 (3):350–354. 15228258
36. Thakur CP, Narain S, Kumar N, Hassan SM, Jha DK, Kumar A, Amphotericin B is superior to sodium antimony gluconate in the treatment of post-kala azar dermal leishmaniasis. Ann Trop Med Parasitol.1997; 91: 611–616. 9425363